KALA BIO, Inc. carries no debt; cash flow comfortably covers obligations.

KALA BIO, Inc.'s free cash flow has decreased 8.11% from $-29.59M last year to $-31.99M, signaling decreasing performance

KALA BIO, Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

KALA BIO, Inc.'s debt has decreased relative to shareholder equity from 2.62 last year to 0.00 today, signaling strengthened financials

KALA BIO, Inc. has a net cash position, so leverage is healthy.

KALA BIO, Inc. carries no debt; interest obligations are fully covered.

KALA BIO, Inc. has insufficient data to evaluate this check.

KALA BIO, Inc.'s short-term assets of $9.49M exceed its short-term liabilities of $2.49M

KALA BIO, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

KALA BIO, Inc.'s return on equity of -1.34K%, is lower than 15.00%, indicating bad performance

KALA BIO, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

KALA BIO, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

KALA BIO, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

KALA BIO, Inc. has negative free cash flow, indicating cash burn

KALA BIO, Inc.'s yearly earnings has increased -29.94% since last year from $-38.51M to $-26.98M, signaling increasing performance

KALA BIO, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -281.52% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

KALA BIO, Inc.'s 3-year revenue CAGR of -100.00% is negative, indicating declining revenue over the past 3 years

KALA BIO, Inc. had revenue growth in 3 out of 5 years, indicating consistent revenue performance

KALA BIO, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

KALA BIO, Inc. has insufficient data to evaluate this check.

KALA BIO, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

KALA BIO, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

KALA BIO, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

KALA BIO, Inc. has insufficient data to evaluate this check.

KALA BIO, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

KALA BIO, Inc. has a price-to-book ratio of 0.57x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

KALA BIO, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue